<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Biosynthesis of specialized proresolving mediators (SPMs)" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">A hostâ€™s normal protective response to tissue injury or pathogenic infection is acute inflammation. The condition of acute inflammation is created by the release of pro-inflammatory lipid mediators such as leukotrienes (LTs) and prostaglandins (PGs) that launch a series of signaling cascades to destroy invading pathogens and to repair damaged tissue (Libby 2007). The potent chemotactic agent leukotriene B4 (LTB4) promotes the recruitment of neutrophils (PMNs) to inflamed tissues, while the prostaglandins E2 and D2 (PGE2 and PGD2) further accelerate the inflammatory process. If left unchecked, the inflammatory response can initiate chronic systemic inflammatory disorders associated with cardiovascular disease, rheumatoid arthritis, periodontal disease, asthma, diabetes, inflammatory bowel disease (IBD), Alzheimerâ€™s disease and age-related macular degeneration (AMD). The specific role by which inflammation contributes to their pathogenesis is not fully understood.&lt;br&gt;&lt;br&gt;To prevent the onset of chronic inflammation, a &lt;i&gt;lipid mediator class switch&lt;/i&gt; is thought to occur from the initial actions of pro-inflammatory lipid mediators to the anti-inflammatory and pro-resolving actions of lipoxins, resolvins, protectins and maresins (collectively called specialized proresolving mediators (SPMs)). Nanopicogram quantities of different lipid mediators are generated at different times during the evolution of the inflammatory response and these mediators coincide with distinct cellular events. The class switch activates leukocyte translational regulation of the enzymes required to produce pro-resolving lipid mediators (Levy et al. 2001). Each family of these PSMs exert specialized actions, including blocking neutrophil recruitment, promoting the recruitment and activation of monocytes, as well as mediating the nonphlogistic phagocytosis and lymphatic clearance of apoptotic neutrophils by activated macrophages (ie without inducing inflammation) and mediating tissue regeneration. Eventually, through the combined actions of these mediators, the resolution of inflammation is completed and homeostasis is reached (Serhan 2010, Bannenberg &amp; Serhan 2010, Freire &amp; Van Dyke 2013, Serhan et al. 2014).&lt;br&gt;&lt;br&gt;SPMs are derived from polyunsaturated fatty acids (PUFAs) (Molfino et al. 2017). PUFAs of the Ï‰-3 series are essential nutrients since they cannot be produced by humans (Duvall &amp; Levy 2016) and are primarily found in dietary fish oils (Calder 2013) and in plants (Baker et al. 2016). The Ï‰-3 PUFAs eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-3) circulate in the bloodstream after dietary intake and are easily incorporated into cellular membranes in a time- and dose-dependent manner (Calder 2009), as well as being present in inflammatory exudates (Kasuga et al. 2008). They can be mobilised by phospholipase A2 from cellular membranes on injury or infection when they are converted to exudate SPMs (Serhan et al. 2002) to interact with local immune cells (Kasuga et al. 2008). EPA is the source for E-series resolvins while DHA is the source for D-series resolvins, protectins, maresins and sulfido conjugates in tissue regeneration mediators (Serhan et al. 2017). The Ï‰-6 fatty acid arachidonic acid (AA) is the source for lipoxins. Ï‰-3 or Ï‰-6 PUFA docosapentaenoic acids (DPAn-3 and DPAn-6) are the sources of DPA-derived resolvins, protectins and maresins (Vik et al. 2017). Aspirin can also trigger the production of epimeric SPMs via acetylated PTGS2 (prostaglandin G/H synthase, COX2) (Serhan &amp; Chiang 2002). Combinations of oxidation, reduction and hydrolysis can generate numerous SPMs. Electrophilic oxo-derivatives of Ï‰-3 PUFAs are a class of oxidised derivatives that are generated in macrophages and neutrophils by the actions of 5-lipoxygenase, cyclooxygenase-2 and acetylated cyclooxygenase-2, followed by dehydrogenation. Being electrophilic, oxo-derivative SPMs reversibly bind to nucleophilic residues on target proteins, triggering the activation of cytoprotective pathways (Cipollina 2015). The pathways in this section describe the biosynthesis of these SPMs.
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=9018678 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 9018678</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Jassal, Bijay</Comment>
  <BiopaxRef>abd</BiopaxRef>
  <BiopaxRef>d6e</BiopaxRef>
  <BiopaxRef>eeb</BiopaxRef>
  <BiopaxRef>da3</BiopaxRef>
  <BiopaxRef>c9b</BiopaxRef>
  <BiopaxRef>ba2</BiopaxRef>
  <BiopaxRef>a9c</BiopaxRef>
  <BiopaxRef>d07</BiopaxRef>
  <BiopaxRef>ec5</BiopaxRef>
  <Attribute Key="reactome_id" Value="9018678" />
  <Graphics BoardWidth="492.0" BoardHeight="258.0" />
  <DataNode TextLabel="Biosynthesis of&#xA;EPA-derived SPMs" GraphId="afd58" Type="Pathway">
    <Comment Source="Reactome">Eicosapentaenoic acid (EPA), a major Ï‰-3 polyunsaturated fatty acid (PUFA) found in fish oil is the source of E-series resolvins (RvEs), one of the specialized proresolving mediators (SPMs) that show potent anti-inflammatory and pro-resolving actions (Molfino et al. 2017). The biosynthesis of RvEs occurs mainly during the process of inflammation when endothelial cells interact with leukocytes. EPA, circulating in plasma or released/mobilised from damaged cellular membranes on injury or infection, moves with edema into the tissue sites of acute inflammation where it is converted to exudate RvEs to interact with local immune cells (Kasuga et al. 2008). The initial transformation of EPA by aspirin-acetylated cyclooxygenase 2- and/or cytochrome P450-mediated catalysis can produce stereospecific resolvins (18(R)- or 18(S)-RvEs). Combinations of oxidation, reduction and hydrolysis reactions determine the type of resolvin formed (RvE1, RvE2 or RvE3) (Serhan et al. 2000, 2002, Serhan &amp; Petasis 2011, Maehre et al. 2015). </Comment>
    <BiopaxRef>e5c</BiopaxRef>
    <BiopaxRef>b10</BiopaxRef>
    <BiopaxRef>ba2</BiopaxRef>
    <BiopaxRef>e01</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="239.5" CenterY="65.0" Width="131.0" Height="72.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9018679" />
  </DataNode>
  <DataNode TextLabel="Biosynthesis of&#xA;DHA-derived SPMs" GraphId="b05ac" Type="Pathway">
    <Comment Source="Reactome">Docosahexaenoic acid (DHA), a major Ï‰-3 polyunsaturated fatty acid (PUFA) found in fish oil is the source of D-series resolvins (RvDs), one of the specialized proresolving mediators (SPMs) that show potent anti-inflammatory and pro-resolving actions (Molfino et al. 2017). The biosynthesis of RvDs occurs mainly during the process of inflammation when endothelial cells interact with leukocytes. Dietary DHA circulates in plasma or is present in cellular membranes as it can easily integrate into membranes. On injury or infection, DHA moves with edema into the tissue sites of acute inflammation where it is converted to exudate RvDs to interact with local immune cells (Kasuga et al. 2008). The initial transformation of DHA by aspirin-acetylated cyclooxygenase-2 or cyclooxygenase-mediated catalysis can produce stereospecific D-resolvins (18(R)- or 18(S)-RvDs respectively). Combinations of oxidation, reduction and hydrolysis reactions determine the type of D-resolvin formed (RvD1-6) (Serhan et al. 2002, Serhan &amp; Petasis 2011, Serhan et al. 2014). </Comment>
    <BiopaxRef>e5c</BiopaxRef>
    <BiopaxRef>abd</BiopaxRef>
    <BiopaxRef>ba2</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="395.0" CenterY="72.0" Width="134.0" Height="70.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9018677" />
  </DataNode>
  <DataNode TextLabel="Biosynthesis of&#xA;DPA-derived SPMs" GraphId="c297a" Type="Pathway">
    <Comment Source="Reactome">Docosapentaenoic acid (DPA), a C22:5 long-chain Ï‰3 or Ï‰6 polyunsaturated fatty acid (PUFA), is found in algal and fish oils, created via linoleic acid metabolism and is a metabolite in DHA metabolism. It can be acted upon by lipoxygenases to produce mono-, di- and tri-hydroxy derivatives in neutrophils and macrophages. These DPA derivatives are another branch of the specialised proresolving mediators (SPMs) produced from long-chain fatty acids which have anti-inflammatory properties, even though mechanisms of their anti-inflammatory action have not been fully elucidated (Bannenberg &amp; Serhan 2010, Dangi et al. 2010, Vik et al. 2017, Hansen et al. 2017).&lt;br&gt;&lt;br&gt;The biosynthesis of SPMs derived from the two isomers of DPA, DPAn-6 (cis-4,7,10,13,16-docosapentaenoic acid) and DPAn-3 (cis-7,10,13,16,19-docosapentaenoic acid), is described here. The only difference between the two isomers is the position of the first double bond; Ï‰-3 for DPAn-3 and Ï‰-6 for DPAn-6. The products of these isomers were characterised by analogy in structure and action to docosahexaenoic acid (DHA)-derived and eicosapentaenoic acid (EPA)-derived resolvins, protectins and maresins (Serhan et al. 2002, Bannenberg &amp; Serhan 2010, Serhan et al. 2015).</Comment>
    <BiopaxRef>eeb</BiopaxRef>
    <BiopaxRef>a9c</BiopaxRef>
    <BiopaxRef>f54</BiopaxRef>
    <BiopaxRef>aac</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="117.0" CenterY="172.5" Width="134.0" Height="67.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9018683" />
  </DataNode>
  <DataNode TextLabel="Biosynthesis of&#xA;electrophilic Ï‰-3&#xA;PUFA&#xA;oxo-derivatives" GraphId="e27fe" Type="Pathway">
    <Comment Source="Reactome">Electrophilic oxo-derivatives of Ï‰-3 polyunsaturated fatty acids (Ï‰-3 PUFAs) are generated in macrophages and neutrophils in response to inflammation and oxidative stress to promote the resolution of inflammation. Being electrophilic, these derivatives reversibly bind to nucleophilic residues on target proteins (thiolates of cysteines and amino groups of histidine and lysine), triggering the activation of cytoprotective pathways. These include the Nrf2 antioxidant response, the heat shock response and the peroxisome proliferator activated receptor Î³ (PPARÎ³) and suppressing the NF-ÎºB proinflammatory pathway (Cipollina 2015). Thus, these electrophilic derivatives transduce anti-inflammatory actions rather than suppress the production of pro-inflammatory arachidonic acid metabolites. An oxo-derivative of EPA has been shown to ablate leukemia stem cells in mice, which may represent a novel chemoprotective action for some oxo-derivatives (Hedge et al. 2011, Finch et al. 2015). In humans, dietary supplementation with Ï‰-3 PUFAs has been reported to increase the formation of oxo-derivatives (Yates et al. 2014). The enzymes cyclooxygenases (COX), lipoxygenases (LOs) and cytochromes P450s, acting alone or in concerted transcellular biosynthesis, initially form epoxy or hydroxy intermediates of Ï‰-3 PUFAs docosahexaenoic acid (DHA), docosapentaenoic acid (DPAn-3) and eicosapentaenoic acid (EPA) before these are further oxidised to electrophilic Î±,Î²-unsaturated keto-derivatives by cellular dehydrogenases.</Comment>
    <BiopaxRef>ec5</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="302.0" CenterY="183.0" Width="164.0" Height="90.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9027604" />
  </DataNode>
  <DataNode TextLabel="Synthesis of&#xA;Lipoxins (LX)" GraphId="a7d8c" Type="Pathway">
    <Comment Source="Reactome">Lipoxins A4 (LXA4) and B4 (LXB4), structurally characterized from human neutrophils incubated with 15-hydroperoxy-eicosatetraenoic acid (15-HpETE), each contain three hydroxyl moieties and a conjugated tetraene. The third hydroxyl of LXA4 is positioned at C-6, and of LXB4 at C-14.  The action of arachidonate 5-lipoxygenase (ALOX5), in concert with an arachidonate 12-lipoxygenase (ALOX12) or arachidonate 15-lipoxygenase (ALOX15) activity, has been shown to produce lipoxins by three distinct pathways.  Neutrophil ALOX5 can produce and secrete leukotriene A4 (LTA4) that is taken up by platelets, where it is acted upon by ALOX12 to form lipoxins. Likewise, ALOX15s can generate either 15-hydroperoxy-eicosatetraenoic acid (15-HpETE) or 15-hydro-eicosatetraenoic acid (15-HETE) that can be taken up by monocytes and neutrophils, where highly expressed ALOX5 uses it to generate lipoxins. Finally, aspirin acetylated prostaglandin G/H synthase 2 (PTGS2), rendered unable to synthesize prostaglandins, can act as a 15-lipoxygenase. This leads to the formation of 15R-HETE and culminates in creation of epi-lipoxins, which have altered stereochemistry at the C-15 hydroxyl but similar biological potency (Chiang et al. 2006, Buczynski et al. 2009, Vance &amp; Vance 2008, Stsiapanava et al. 2017).</Comment>
    <BiopaxRef>ced</BiopaxRef>
    <BiopaxRef>a68</BiopaxRef>
    <BiopaxRef>c44</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="94.0" CenterY="68.5" Width="114.0" Height="73.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-2142700" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="abd">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25359497</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lipid mediators in the resolution of inflammation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Serhan CN, Chiang N, Dalli J, Levy BD.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d6e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23931059</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Natural resolution of inflammation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Freire MO, Van Dyke TE.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="eeb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">20708099</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Specialized pro-resolving lipid mediators in the inflammatory response: An update.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bannenberg G, Serhan CN.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="da3">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">20813960</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Serhan CN.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c9b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11429545</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lipid mediator class switching during acute inflammation: signals in resolution.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ba2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12391014</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a9c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28408222</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Recent advances in the chemistry and biology of anti-inflammatory and specialized pro-resolving mediators biosynthesized from n-3 docosapentaenoic acid.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vik A, Dalli J, Hansen TV.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d07">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28802833</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Serhan CN, Chiang N, Dalli J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ec5">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26339618</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Endogenous Generation and Signaling Actions of Omega-3 Fatty Acid Electrophilic Derivatives.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cipollina C.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e5c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21766791</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Resolvins and protectins in inflammation resolution.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Serhan CN, Petasis NA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b10">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26393581</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ω-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Maehre HK, Jensen IJ, Elvevoll EO, Eilertsen KE.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e01">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11034610</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f54">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28602942</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The novel lipid mediator PD1&lt;sub&gt;n-3 DPA&lt;/sub&gt;: An overview of the structural elucidation, synthesis, biosynthesis and bioactions.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hansen TV, Dalli J, Serhan CN.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="aac">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19679107</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Metabolism and biological production of resolvins derived from docosapentaenoic acid (DPAn-6).</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dangi B, Obeng M, Nauroth JM, Chung G, Bailey-Hall E, Hallenbeck T, Arterburn LM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ced">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16968948</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DW, Rovati GE, Shimizu T, Yokomizo T, Brink C.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a68">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19244215</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Buczynski MW, Dumlao DS, Dennis EA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c44">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28827365</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Capturing LTA&lt;sub&gt;4&lt;/sub&gt; hydrolase in action: Insights to the chemistry and dynamics of chemotactic LTB&lt;sub&gt;4&lt;/sub&gt; synthesis.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stsiapanava A, Samuelsson B, Haeggström JZ.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

